perampanel

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Central Nervous System

Conditions

Central Nervous System

Trial Timeline

Jan 1, 2012 → Apr 1, 2015

NCT ID

NCT01527006

About perampanel

perampanel is a phase 2 stage product being developed by Eisai for Central Nervous System. The current trial status is completed. This product is registered under clinical trial identifier NCT01527006. Target conditions include Central Nervous System.

What happened to similar drugs?

4 of 20 similar drugs in Central Nervous System were approved

Approved (4) Terminated (2) Active (14)

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

✅Pregabalin + PlaceboPfizerApproved

✅Aflibercept (2.0 mg)Regeneron PharmaceuticalsApproved

✅Aflibercept (Eylea, BAY86-5321)BayerApproved

🔄Placebo + MirogabalinDaiichi SankyoPhase 3

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄Leuprolide Acetate (LA)AbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01871233	Pre-clinical	Completed	—	—	Partial Onset Seizures
NCT02307578	Pre-clinical	Completed	—	—	Primary Generalized Tonic-Clonic or Partial Onset Seizures
NCT05533814	Approved	Completed	Oct 19, 2022	Jan 23, 2025	Epilepsy
NCT04252846	Pre-clinical	Completed	Jul 20, 2020	Jan 12, 2023	Idiopathic Generalized Epilepsy
NCT03836924	Pre-clinical	Completed	Feb 18, 2019	Mar 1, 2020	Partial Onset Seizures
NCT03424564	Phase 1	Completed	Mar 20, 2018	May 25, 2018	Healthy Subjects
NCT03288129	Approved	Completed	Aug 23, 2017	Apr 27, 2021	Partial Onset Seizures
NCT02914314	Phase 2	Completed	Feb 20, 2017	Apr 25, 2023	Epilepsy
NCT02849626	Phase 3	Completed	Nov 16, 2016	Dec 6, 2021	Partial-Onset or Primary Generalized Tonic-Clonic Seizures
NCT02726074	Approved	Completed	May 3, 2016	Apr 26, 2018	Epilepsy
NCT04230044	Pre-clinical	Completed	Apr 11, 2016	Jul 3, 2017	Epilepsy
NCT04257604	Pre-clinical	Completed	Jan 3, 2016	Apr 30, 2019	Partial Seizures
NCT02727101	Approved	Terminated	Nov 1, 2015	Jul 1, 2017	Epilepsy
NCT02427607	Phase 3	Completed	May 12, 2015	Nov 9, 2016	Epilepsy
NCT02279485	Phase 1	Completed	Sep 1, 2014	Jan 1, 2015	Healthy Subjects
NCT02033902	Pre-clinical	Completed	Jun 6, 2014	Jan 31, 2018	Epilepsy
NCT01527006	Phase 2	Completed	Jan 1, 2012	Apr 1, 2015	Central Nervous System
NCT00903786	Phase 2	Completed	Jun 17, 2009	Oct 31, 2016	Refractory Partial Seizures
NCT00735397	Phase 3	Completed	Oct 1, 2008	Sep 1, 2014	Epilepsy
NCT00505622	Phase 3	Terminated	Jul 1, 2007	Apr 1, 2008	Parkinson's Disease

Competing Products

20 competing products in Central Nervous System

See all competitors

Product	Company	Stage	Hype Score
Placebo + Mirogabalin	Daiichi Sankyo	Phase 3	40
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	43
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol	Eisai	Phase 1	29
Tirabrutinib + Placebo	Ono Pharmaceutical	Phase 2	42
Tirabrutinib	Ono Pharmaceutical	Phase 1	36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + Vincristine	Ono Pharmaceutical	Phase 1	33
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Tirabrutinib + Tirabrutinib + Tirabrutinib	Ono Pharmaceutical	Phase 2	39
pemetrexed	Eli Lilly	Phase 1	29
HRS-9231 + Gadobutrol	Jiangsu Hengrui Medicine	Phase 2	42
Leuprolide Acetate (LA)	AbbVie	Phase 3	40
Acalabrutinib	AstraZeneca	Phase 2	39
Durvalumab + Acalabrutinib	AstraZeneca	Phase 1	33
Avelumab + Lenvatinib	Merck	Phase 1	33
temozolomide	Merck	Phase 3	44
Ibrutinib + Pembrolizumab + Rituximab	Merck	Phase 1/2	39
Temozolomide	Merck	Phase 2	35
Verteporfin + ranibizumab	Novartis	Phase 1/2	32